Ireland· IE-PA-EU/1/22/1687/001-002
Enjaymo 50 mg/mL solution for infusion
A sutimlimab product containing sutimlimab, registered in Ireland by Recordati Rare Diseases. The same ATC class is registered in 2 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Sutimlimab is registered in 2 of 19 countries.
Countries holding a registration under ATC L04AA55 (sutimlimab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 1 of them publish a price we can compare per daily dose
Sutimlimab · ATC L04AA55
2 / 19 countries
- Belgiumprice
- Ireland
The record
At a glance
HPRA (Ireland)- Active substance
- Sutimlimab
- Manufacturer
- Recordati Rare Diseases
- Country
- Ireland (IE)
- ATC code
- L04AA55
- ATC class
- Sutimlimab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1687/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sutimlimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandEnjaymo 1100 mg/22 ml, InfusionslösungRECORDATI AG
- CzechiaENJAYMORecordati Rare Diseases, Puteaux
- FinlandEnjaymoRecordati Rare Diseases
- IcelandEnjaymoRecordati Rare Diseases
- NorwayEnjaymoRecordati Rare Diseases
- PolandEnjaymoSanofi B.V.
- BelgiumEnjaymo 50 mg/mlRecordati Rare Diseases
- SwedenEnjaymo 50 mg/mL Infusionsvätska, lösningRecordati Rare Diseases
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enjaymo
- Liechtenstein · Enjaymo
- Norway · Enjaymo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/04166320-ce66-4b21-a1f5-c78803380a17 GET /v1/drugs/04166320-ce66-4b21-a1f5-c78803380a17?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L04",
"L04AA55"
],
"strength": null,
"pa_number": "EU/1/22/1687/001-002",
"substances": [
"Sutimlimab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "15/11/2022",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about sutimlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.